-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Oncolytic Virus To Target CD46 And SLC5A5 For Oncology in Recurrent Medulloblastoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Oncolytic Virus To Target CD46 And SLC5A5 For Oncology in Recurrent Medulloblastoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Oncolytic Virus To Target...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Oncolytic Virus To Target CD46 And SLC5A5 For Oncology in Atypical Teratoid Rhabdoid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Oncolytic Virus To Target CD46 And SLC5A5 For Oncology in Atypical Teratoid Rhabdoid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Oncolytic Virus...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Voyager-V1 in Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Voyager-V1 in Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Voyager-V1 in Colorectal Cancer Drug Details: Voyager-V1 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Voyager-V1 in Endometrial Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Voyager-V1 in Endometrial Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Voyager-V1 in Endometrial Cancer Drug Details: Voyager-V1 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Voyager-V1 in Head And Neck Squamous Cell Carcinoma (HNSC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Voyager-V1 in Head And Neck Squamous Cell Carcinoma (HNSC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Voyager-V1 in Head And Neck Squamous...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Oncolytic Virus To Target CD46 And SLC5A5 For Oncology in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Oncolytic Virus To Target CD46 And SLC5A5 For Oncology in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Oncolytic Virus...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Dostarlimab in Non-Small Cell Lung Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dostarlimab in Non-Small Cell Lung Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dostarlimab in Non-Small Cell Lung Carcinoma Drug Details: Dostarlimab (Jemperli)...
-
Product Insights
Atypical Teratoid Rhabdoid Tumor – Drugs In Development, 2023
Global Markets Direct’s, ‘Atypical Teratoid Rhabdoid Tumor - Drugs In Development, 2023’, provides an overview of the Atypical Teratoid Rhabdoid Tumor pipeline landscape. The report provides comprehensive information on the therapeutics under development for Atypical Teratoid Rhabdoid Tumor, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Pheochromocytoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Pheochromocytoma - Drugs In Development, 2023’, provides an overview of the Pheochromocytoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Pheochromocytoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Neurofibromatoses – Drugs In Development, 2023
Global Markets Direct’s, ‘Neurofibromatoses - Drugs In Development, 2023’, provides an overview of the Neurofibromatoses pipeline landscape. The report provides comprehensive information on the therapeutics under development for Neurofibromatoses, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...